JEADV clinical practice最新文献

{"title":"Editor's Picks","authors":"","doi":"10.1002/jvc2.70060","DOIUrl":"https://doi.org/10.1002/jvc2.70060","url":null,"abstract":"","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 2","pages":"375-377"},"PeriodicalIF":0.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.70060","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating Quality of Care Indicators for Metastasis Development in Cutaneous Squamous Cell Carcinoma Among Mexican Renal Transplant Recipients","authors":"Andrea Malagon-Liceaga, Jesus Alejandro Romero-Aguila, Bonfilio Roberto Lazcano-Prieto, Fanny Carolina Lopez-Jimenez, Rebeca Palafox-Romo, Samantha Paola Bermudez Rodriguez, Verónica Monserrat Díaz Sanchez, Judith Dominguez-Cherit, Silvia Mendez-Flores, Ana Lilia Ruelas-Villavicencio","doi":"10.1002/jvc2.70030","DOIUrl":"https://doi.org/10.1002/jvc2.70030","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Cutaneous squamous cell carcinoma (cSCC) poses a high metastatic risk in immunosuppressed individuals, especially organ transplant recipients (OTRs). Despite international guidelines recognizing these risks, no universal standard exists for assessing quality of care (QoC) in cSCC. QoC indicators, as defined by NICE, ensure evidence-based management, including histopathology, treatment timelines, and follow-up, yet adherence remains challenging, particularly in low- and middle-income countries.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To evaluate the occurrence of metastasis in cSCC among Mexican renal transplant recipients (RTRs) and assess how QoC indicators influenced this outcome.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Analysis of a subgroup of patients with invasive cSCC from a cohort of 1642 RTRs, excluding keratoacanthomas, SCC in situ, and externally treated tumors, leaving 123 cases. QoC indicators included pathology report completeness, diagnosis-to-surgery time, follow-up duration, and surgical team involvement. Comprehensive reports documented tumor size, depth, differentiation, and perivascular/perineural invasion. Statistical analysis included Fisher's exact test, Wilcoxon-Mann-Whitney test, and LASSO logistic regression.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among the 123 tumors, 4.9% metastasized, 83.3% in men. Notably, 19.4% of tumors had a comprehensive pathology report. The AJCC 7 guidelines in 2015 improved reporting quality, with 30.5% of reports meeting comprehensive criteria post-2015, compared to 9.4% before (<i>p</i> = 0.005). LASSO logistic regression identified predictors of metastasis: tumor differentiation (OR 3.0, 95%CI: 2–4.5), reporting tumor depth (OR 1.4, 95%CI: 1.2–1.7), and reporting perivascular invasion (OR 8.66, 95%CI: 4.8–15.6). This suggests that pathologists may have been more likely to document aggressive-looking tumors. Time to surgery was similar across cases, but multidisciplinary teams were more involved in metastatic cases.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The lack of universally recognized QoC guidelines for cSCC treatment in OTRs presents a significant gap in patient care. Standardized reporting and treatment protocols, similar to melanoma guidelines, could improve outcomes and support research like ours. The study's retrospective nature and missing data require cautious interpretation.</p>\u0000 </section>\u0000 ","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 2","pages":"499-502"},"PeriodicalIF":0.0,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.70030","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “Successful Treatment of Pyoderma Gangrenosum With Guselkumab”","authors":"","doi":"10.1002/jvc2.70031","DOIUrl":"https://doi.org/10.1002/jvc2.70031","url":null,"abstract":"<p>S. Botvid, C. Zachariae, Skov, L., and J. Ferløv Schwensen. “Successful Treatment of Pyoderma Gangrenosum With Guselkumab.” <i>JEADV Clinical Practice</i> 4, no. 1 (2025): 229. https://doi.org/10.1002/jvc2.522</p><p>Under the subheading “Case Report” of Case 1, line 8–9, the current text states: “Starting in November 2022, the patient was treated with injections (off-label) of guselkumab 400 mg, every sixth week.”</p><p>However, the correct dosage should be “<b>100 mg,</b> every sixth week” rather than 400 mg.</p><p>We sincerely apologize for this error.</p>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.70031","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Livedoid Vasculopathy Successfully Treated With JAK Inhibitors","authors":"Antoine Delpuech,&nbsp;Emilie Tournier,&nbsp;Pierre Sohier,&nbsp;Nicolas Dupin,&nbsp;Chloe Challamel,&nbsp;Sara Altandi,&nbsp;Serge Boulinguez,&nbsp;Carle Paul","doi":"10.1002/jvc2.593","DOIUrl":"https://doi.org/10.1002/jvc2.593","url":null,"abstract":"<p>Livedoid vasculopathy is a rare thrombotic disease of the small blood vessels. It manifests as fixed violaceous macules, noninflammatory retiform purpura, painful ulcers, and white atrophic scars on the lower extremities. The pathophysiology involves the type 1 interferon pathway. Many patients do not improve with oral anticoagulants. We report here two cases of patients with refractory livedoid vasculopathy treated successfully with JAK inhibitors. The first patient was treated with baricitinib with complete remission of leg ulcers after 4 months of treatment. The second patient was treated with upadacitinib and achieved complete remission after 6 months of treatment. Clinical and biological tolerability was excellent in both patients. JAK inhibitors, through their effect on the interferon pathway, may be a promising treatment for livedoid vasculopathy.</p>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 2","pages":"514-518"},"PeriodicalIF":0.0,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.593","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world experience of adjuvant immunotherapy for stages III–IV melanoma: A monocentric observational study","authors":"Manon Blaise,&nbsp;Eric Fontas,&nbsp;Barbara Seitz-Polski,&nbsp;Laura Troin,&nbsp;Alexandra Picard,&nbsp;Perrine Rousset,&nbsp;Elodie Long-Mira,&nbsp;Micheline Razzouk-Cadet,&nbsp;Madleen Chassang,&nbsp;Thierry Passeron,&nbsp;Henri Montaudié","doi":"10.1002/jvc2.571","DOIUrl":"https://doi.org/10.1002/jvc2.571","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Adjuvant immunotherapy (AIO) improved recurrence-free survival (RFS) in patients with resected stages III–IV melanoma. Real-world data, especially in elderly patients, as well as optimal management of patients who relpases, are still limited.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To evaluate real-world outcomes of AIO in a cohort of stages III–IV melanoma patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a monocentric, retrospective, observational study that included patients treated with AIO (nivolumab or pembrolizumab) for stages III/IV melanoma. The primary endpoint was RFS. Subgroup analyses were performed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 76 patients were included, with a mean age of 64.6 years (51.3% and 31.6 age ≥65 and ≥75 years, respectively). Majority received nivolumab (67.1%). Median follow-up period was 26.4 months (interquartile range, 17.9–35.1 months). The RFS rates for the whole cohort were 75.8%, 66.0%, 52.9% and 52.9% for 1, 2, 3 and 4 years, respectively. Patients aged &lt;75 years had a better RFS rate compare to those older ≥75 years (60.4% vs. 38.3% respectively, <i>p </i>= 0.02). A total of 41 patients (53.9%) experienced immune-related adverse events (irAEs) of any grade, and 22.3% of grade 3–5. irAEs ≥ 3 concerned 17.3% of patients aged &lt;75 years and 33.3% for those aged ≥75 years. Thirteen patients (17.1%) had discontinued IO early due to severe irAEs after a median of 2 months (range 1–7). Median time to first recurrence from starting adjuvant programmed cell death 1 was 6.5 months (range, 1–35). Most patients recurred ON adjuvant IO (15/28 patients, 19.7%). Most of the time, first-line therapy after melanoma recurrence was ipilimumab plus nivolumab. Objective response rate was higher for patients with recurrence within 6 months of stopping adjuvant IO (33.3%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Real-world outcomes of AIO for stages III/IV melanoma appeared comparable to clinical trial data. Immunotherapy appears less effective and less well tolerated in elderly patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 2","pages":"425-439"},"PeriodicalIF":0.0,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.571","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Pruritus With Comorbidities and Survival in Myeloproliferative Neoplasms: A Systematic Review of the Literature","authors":"J. Saucereau,&nbsp;E. Brenaut,&nbsp;A. S. Ficheux,&nbsp;L. Misery,&nbsp;C. Le Gall-Ianotto","doi":"10.1002/jvc2.70023","DOIUrl":"https://doi.org/10.1002/jvc2.70023","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Pruritus is a symptom frequently associated with systemic diseases, particularly hematological disorders.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>The aim of this study was to evaluate the association of pruritus with morbidity in myeloproliferative neoplasms (MPN).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A systematic review of the literature was performed using two databases (Pubmed and Embase). Studies were included if they were published between January 2000 and August 2022 and addressed an association between pruritus and morbidity or survival in MPN patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Ten articles were selected for the systematic review, 6 including patients with polycythemia vera (PV), 1 with essential thrombocythemia (ET), 2 with primary myelofibrosis (PMF) and 1 including both ET and PV. While 2 studies found no significant association between pruritus and mortality, 2 studies found a significant association between pruritus and improved survival. Three studies reported a statistically significant association between pruritus and an increase in thromboembolic events, while one study did not. One study showed an association between the presence of pruritus and sleep disturbance in PV. One study demonstrated an association between pruritus and the presence of depressive symptoms in PV. Two studies found a significant association between disease progression and the presence of pruritus, while three studies did not.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>While pruritus appears to influence sleep quality and the onset of depressive symptoms, the effect of pruritus on mortality is more controversial, but the presence of pruritus might be associated with better survival.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> PROSPERO Number</h3>\u0000 \u0000 <p>CRD42022316850.</p>\u0000 </section>\u0000 </div>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 2","pages":"407-415"},"PeriodicalIF":0.0,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.70023","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144190746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of Mild-to-Moderate Atopic Dermatitis With Topical Treatments by Dermatologists: A Questionnaire-Based Study","authors":"Lawrence F. Eichenfield,&nbsp;Linda F. Stein Gold,&nbsp;Adelaide A. Hebert,&nbsp;Lyn Guenther,&nbsp;Yuliya Valdman-Grinshpoun,&nbsp;Dan Ben-Amitai,&nbsp;Roni P. Dodiuk-Gad,&nbsp;Michael J. Cork,&nbsp;Valeria Aoki,&nbsp;Chia-Yu Chu,&nbsp;Jianzhong Zhang,&nbsp;Lin Ma,&nbsp;Hidehisa Saeki,&nbsp;Paula C. Luna,&nbsp;Mark Jean-Aan Koh","doi":"10.1002/jvc2.611","DOIUrl":"https://doi.org/10.1002/jvc2.611","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Atopic dermatitis (AD) is a chronic, immune-mediated, inflammatory skin disorder affecting a heterogeneous population. Most patients with mild-to-moderate AD are treated with topical medication.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To gain an understanding of the management of mild-to-moderate AD with topical treatments by examining the practices of dermatologists worldwide using a questionnaire.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Participants from North America, the Middle East, Asia, South America and the United Kingdom completed an electronic questionnaire composed of 43 questions assessing their clinical practice with topical treatment for patients with mild-to-moderate AD among different age groups ( &lt; 2, 2−12 and &gt; 12 years) and disease severity (mild or moderate AD).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Seventeen dermatologists completed the questionnaire. For patients of all ages with mild-to-moderate AD, nearly all participants indicated that topical corticosteroids (TCSs) are the first-line topical treatment for a duration of ≤ 4 weeks before reassessment. Less-potent TCSs were preferred for younger patients and for sensitive regions of the body. Time until treatment re-evaluation was guided by disease severity: the greater the disease severity, the shorter the time until re-evaluation (1 week to 4 months). In all age groups, after initial treatment, most participants would continue the regimen previously prescribed, switch to a non-TCS agent (e.g., a topical calcineurin inhibitor, crisaborole or topical JAK inhibitor), or reduce the dose. All participants would utilize TCSs with or without non-TCS agents for treating flares depending on patient age and affected region(s) of the skin. Infection, drug-related adverse effects, worsening AD, corticophobia and limited access to topical pharmacologic treatment were the main reasons for deviation from the standard regimen.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Management of mild-to-moderate AD in practice is influenced by several patient-specific factors, access to specialist care and therapies, safety concerns and limitations associated with treatment options.</p>\u0000 </section>\u0000 </div>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 2","pages":"471-481"},"PeriodicalIF":0.0,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.611","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144190736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comorbidities of Primary Scarring Alopecias: A Retrospective Multi-Site Cross-Sectional Study","authors":"Arielle Carolina Mora Hurtado,&nbsp;Sarah Gonzalez,&nbsp;Nicole C. Syder,&nbsp;Arthur Manasyan,&nbsp;Tiana Thompson,&nbsp;Lucy Harvey,&nbsp;Jack Rodman,&nbsp;Nada Elbuluk","doi":"10.1002/jvc2.70015","DOIUrl":"https://doi.org/10.1002/jvc2.70015","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>To date, limited research has compared the systemic comorbidities of primary scarring alopecia types. Such research may provide insight into shared disease mechanisms, elucidate novel pathways for therapeutics, and identify those most at risk of comorbidities.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To evaluate the prevalences of systemic comorbidities among scarring alopecia types and compare the prevalence of these comorbidities with national United States prevalence.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective chart review was conducted investigating the systemic comorbidities in patients with scarring alopecia seen at public and private dermatology clinics in Los Angeles between 2018 and 2022.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 240 patients were identified. Compared to other scarring alopecia types, patients with central centrifugal cicatricial alopecia (CCCA) had an increased risk for concomitant traction alopecia (OR 13.98, <i>p</i> &lt; 0.001), concomitant androgenetic alopecia (OR 3.40, <i>p</i> &lt; 0.001), and vitamin D deficiency (OR 1.97, <i>p</i> = 0.039). Compared to the general US population, patients with scarring alopecia, including CCCA and lichen planopilaris/frontal fibrosing alopecia, had a higher prevalence of vitamin D deficiency, metabolic syndrome, depression, anxiety, thyroid disease, uterine fibroids, anemia, atopy, androgenetic alopecia, and breast cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Larger, prospective, population-based studies involving diverse patient groups are needed to differentiate the rates of comorbidities across scarring alopecia types. Dermatologists should consider a thorough review of systems in their patients with scarring alopecia to screen for associated comorbidities, encourage patients to be up to date with age-appropriate screenings, and consider treatment plans that treat associated dermatologic comorbidities along with the primary scarring alopecia.</p>\u0000 </section>\u0000 </div>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 2","pages":"482-494"},"PeriodicalIF":0.0,"publicationDate":"2025-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.70015","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Systemic Immune-Inflammation Index and Its Association With Biologic Therapy Switching and Response in Psoriasis","authors":"Gregg Murray,&nbsp;Niamh Kearney,&nbsp;Conor Smith,&nbsp;Kieran Carty,&nbsp;Yasmine Safta,&nbsp;Olwyn Conlon,&nbsp;Brian Kirby,&nbsp;Ali Alsharqi","doi":"10.1002/jvc2.70001","DOIUrl":"https://doi.org/10.1002/jvc2.70001","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Biologic therapies have revolutionised psoriasis treatment by targeting immune pathways. Despite these advances, some patients experience suboptimal outcomes, necessitating frequent therapeutic switches. The systemic immune-inflammation index (SII) is a novel biomarker for systemic inflammation. Its role in biologic switching in psoriasis remains unexplored.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To evaluate the association between baseline SII levels and biologic therapy switching in patients with moderate-to-severe psoriasis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This single-centre retrospective cohort study included 98 patients with moderate-to-severe psoriasis initiating biologic therapy in 2017. Patients were followed for 5 years to document biologic switches. Baseline demographics, disease severity, and SII levels were analysed. Statistical comparisons and multinomial logistic regression assessed associations between SII and biologic switching.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of the 98 patients, 48 (49%) switched biologics during follow-up: 23 (23.5%) made a single switch, and 25 (25.5%) were multiple switchers (≥ 2 biologics). Baseline SII was significantly higher in switchers compared to non-switchers (<i>p</i> &lt; 0.001). Mean SII values were 560 (95% CI: 456–663) for non-switchers, 1068 (95% CI: 915–1220) for single switchers, and 1275 (95% CI: 1129–1421) for multiple switchers. Higher PASI, DLQI, psoriatic arthritis (PsA) prevalence, smoking, and body weight were also linked to switching (<i>p</i> &lt; 0.05).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Elevated baseline SII is strongly associated with biologic switching, particularly among multiple switchers, highlighting its potential as a stratification tool. Integrating SII into psoriasis treatment algorithms may enable clinicians to identify high-risk patients early, optimise biologic selection, and improve long-term outcomes. This study underscores the importance of incorporating inflammatory markers into personalised psoriasis management strategies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 2","pages":"495-498"},"PeriodicalIF":0.0,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.70001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144190798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Interconnected World of Dermatology and Ophthalmology","authors":"Gyanesh Rathore,&nbsp;Surajit Gorai,&nbsp;Gitikash Purkayastha,&nbsp;Kinnor Das,&nbsp;Prajwal Pudasaini","doi":"10.1002/jvc2.70014","DOIUrl":"https://doi.org/10.1002/jvc2.70014","url":null,"abstract":"<p>Medicine is a dynamic field that constantly discovers new links between different specialties. Dermatology and Ophthalmology are two related branches of medicine, having many similarities and interactions. The skin and the eyes both encounter various environmental challenges, such as ultraviolet radiation, allergens, infections, and trauma, that can alter their structure and function. Furthermore, many diseases that affect the whole body can also involve the skin and the eyes. The article examines the interrelated world of ophthalmology and dermatology, focusing on genetic diseases, autoimmune diseases, systemic disorders, infections and drug reactions that have both skin and eye manifestations. The article discusses conditions such as diabetes, Stevens-Johnson syndrome, lupus erythematosus, vasculitis, and many more. A comprehensive knowledge about the effects of these diseases is essential for providing holistic medical care to the patients. Therefore, it is important for dermatologists and ophthalmologists to work together more frequently to provide optimal care for patients who suffer from such conditions. The article also emphasizes the role of integrative medicine in improving the health and well-being of patients with skin and eye problems.</p>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 2","pages":"389-399"},"PeriodicalIF":0.0,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.70014","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144190967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}